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INTRODUCTION 
 
AMNIOTIC FLUID 
Amniotic fluid is a clear, mildly yellowish coloured fluid contained in amniotic sac which 
is in circulation around the fetus. It has ennumerous functions which are important for the 
fetus and its development inutero2. 
• It gives a physical space for fetus to develop which is necessary for normal 
musculoskeletal development.  
• It acts as shock absorber thereby protects the fetus from external and internal 
injury, and umbilical cord compression.  
• It helps to prevent infection in the amniotic environment by its bacteriostatic 
property. 
•  It allows and helps in fetal swallowing – essential for the gastrointestinal tract 
development, and also supports in fetal breathing necessary for lung development. 
• It maintains amniotic fluid pressure there by reducing the loss of Lung fluid which 
is an essential component for pulmonary development (Nicolini,1989)1 
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AMNIOTIC FLUID PRODUCTION 
Before the embryo becomes evident, an amnionic space  is recognized just before the 
time of implantation. 
       In the first and mid trimester, amniotic fluid is formed from  both maternal and fetal 
and compartments. Substances freely cross the  fetal skin and diffuses through the 
amniontrans membranous flow,  across the fetal vessels on the placental surface as well-
intramembranous flow.  
      Thus amniotic fluid present in early gestation is just a dialysate which is identical to 
maternal and fetal plasma, but its  proteinconcentration is comparatively low with the 
maternal plasma. 
       Fetal urine production starts between 8 to 11 weeks but it is only by 20th week that it 
become the major component. Water transport across the fetal skin continues until about 
22 to 25 weeks, till fetal skin  keratinization takes place, because it makes impermeable 
to further most diffusion.(1) At this point of time, the fetus solely contributes to the 
amniotic fluid volume and also its composition  exclusively through urine. Urine can be 
observed in  fetal bladder at 11 weeks transabdominally , between 3 to 9 weeks by 
transvaginally. Since fetal urine is hypotonic amounting to 80-140 mOsm/liter , it leads to 
hypotonic fluid 250-260 mOsm/liter at term containing increasing concentrations of uric 
acid,  urea and creatinine. 
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        Around term a fetus has the capacity to produce around 500 to 700 ml /day, but it 
begins to decline in urine production hourly after 40 weeks of gestation(15). 
AMNIOTIC FLUID REGULATION 
Amniotic fluid is regulated primarily by fetal swallowing and this has been observed as 
early in 16 weeks. The fluid gets absorbed through fetal gastrointestinal system and it 
either gets transferred to the maternal circulation or gets recycled back through the 
kidney. 
         Secondary factor that aids in removal of amniotic fluid is through the respiratory 
tract. As early as 11 weeks of gestation, fetal respiratory activity can be observed. As 
amniotic fluid is more hypotonic compared to fetal plasma,when amniotic fluid is 
expressed to the fetal alveolar capillary bed, it results in movement of water from 
amniotic cavity to the fetus. 
       It is also postulated that amniotic fluid  is also removed by continuous flow via 
oncotic and hydrostatic forces. At the chorionic plate, fluid exchange takes place and 
leads to reabsorption of water upto 80 ml/day by fetus. 
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FIG 2: AMNIOTIC FLUID PRODUCTION AND REGULATION 
Last but not the least, placenta itself plays a major role in amniotic fluid regulation The 
fetus capillary interface possessing a large surface area has the ability to magnify smaller 
osmolar gradient between the fetus and the mother, thereby leading to net water transfer 
in larger volumes.This level of water exchange maximally influences intravascular 
volume of the fetus and effectively affects renal blood flow and production of urine. 
AMNIOTIC FLUID VOLUME REGULATION IN LATE PREGNANCY 
PATHWAY EFFECT ON VOLUME APPROXIMATE DAILY 
VOLUME(ml) 
Fetal urination Production 1000 
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Fetal swallowing Resorption 750 
Fetal lung fluid secretion Production 350 
Intramembranous flow Resorption 400 
Transmembranous flow Resorption Minimal 
 
FIG 3: AMNIOTIC FLUID PATHWAYS 
 
 AMNIOTIC FLUID CHARACTERISTICS 
PHYSICAL: It is a clear yellow fluid with a pH around 7.2 and specific gravity of 
1.0069-1.008 
CHEMICAL COMPOSITION : Changes with gestational age. 
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• Water constitutes 98 to 99% of amniotic fluid. 
Amniotic fluid has a huge number of dissolved substances like: 
• Urea 
• Bile pigments 
• Creatinine 
• Glucose 
• Fructose 
• Albumin and globulin 
•  Renin 
• Hormones like progesterone and oestrogen 
• Lipids 
• Enzymes 
• Minerals like Na+, K+, Cl+ 
• Undissolved substances like fetal epithelial cells 
In the second trimester of pregnancy, amniotic fluid has a decreased osmolarity and it 
is similar to dilute urine and substances from metabolites. 
AMNIOTIC FLUID VOLUME (WATER) 
During the period of embryogenesis, Amniotic fluid volume rises in a faster rate 
compared to the size of the embryo. Amniotic fluid is mainly produced from the 
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maternal plasma by its passage through the fetal membranes based on osmotic and 
hydrostatic forces.  
In  early fetal period, Amniotic fluid volume and the size of the fetus grows in a 
linear trend. It is evidenced that amniotic fluid volume begins to increase from 25 ml 
at 10 weeks of gestation to about 400 ml in 20 weeks. During this period, its 
composition is almost similar to the fetal plasma.  
A bi directional diffusion takes place between the amniotic fluid and the fetus across 
the non keratinized fetal skin. During this period, amniotic fluid serves as an 
extension of extracellular compartment of the fetus as well as a physiologic buffer, 
In the mid second and in third trimester 
At 19 to 20 weeks of gestation, fetal skin begins to keratinize and the same  usually 
gets completed by 25 weeks of conception.Internal homeostasis of  Amniotic fluid 
volume is well balanced by inflow and outflow pathway.Inflow pathway includes 
fetal urine and lung fluid secretion. Outflow pathway includes swallowing and 
intermembranous absorption of amniotic fluid. 
         Amniotic fluid production is predominantly constituted by  fetal urine –
around 300 ml/kg of fetal weight/day to 600 - 1200 ml/day at term and lung fluid 
production – about 60-100 ml/kg fetal weight/day(16). Efflux of lung secretions into 
AF is mainly contributed by fetal breathing movements. Also it is contributed by oral, 
tracheal and nasal secretions. 
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    Amniotic fluid removal is primarily accomplished by fetal swallowing- about 
200 to 250 ml/kg of fetal weight per day. 
Also an intra-membranous pathway helps in transferring fluid and solutes- 200 to 
500 ml/day from  amniotic sac to entire fetal circulation crossing through the amniotic 
membrane(17,18). 
     Evidence from studies indicates that increased VEGF gene expression(19) in fetal 
membranes is related with high transfer of amniotic fluid into the fetal circulation.   
Also presence of aquaporin protein channels(20) in fetal membranes suggests that 
water channels are another potentiating regulator of water between amnion and 
placenta.  
Trans membrane pathway affects amniotic volume only  to a minimal extent .It 
allows direct exchange of substances across the fetal membranes to the maternal 
circulation accounting to 10 ml/day at term(16). 
  Studies reveal that Hormonal changes play a vital role in regulation of amniotic 
fluid. It has proposed that prolactin(21) present in the decidua exerts an effect on 
amniotic permeability. Many other hormone related mechanisms are under research. 
        Uterine perfusion helps in regulation of amniotic fluid. It has proposed that 
maternal dehydration inturn leads to increased production of vasopressin and arginine 
as well as increase in fetal plasma osmolality. Thereby this inturn leads to increase in 
osmolaltity of fetal urine(22). 
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      Amniotic fluid volume, a perfectly regulated process is  dependent on the 
respective gestational age,and it is maintained within a specific fixed range. The 
amniotic fluid volume peaks between  36 and 38 weeks of about 800-1000 ml and 
therefore declines to about 400 ml at 42 weeks. 
 
FIG 4: AMNIOTIC FLUID MECHANISM 
AMNIOTIC FLUID: DISSOLVED SUBSTANCES 
NUTRIENTS 
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      Amniotic fluid constitutes  carbohydrates, peptides and proteins, lactate, lipids, 
pyruvate, enzymes electrolytes and hormones. 
      Taurine is rich in amniotic fluid and it is the only amino acid present in larger 
quantity than its concentration in maternal and fetal blood. Whereas other amino acids 
are present in lower concentrations in amniotic fluid. 
Glutamine in amniotic fluid plays a precursor role in nucleic acid synthesis for all the 
cells and also helps in proliferation of rapidly dividing cells especially intestinal 
mucosa cells. 
Arginine plays a key role in development of both fetus and placenta. Arginine is 
usually hydrolyzed to ornithine, which in turn is converted to polyamines(23),spermine, 
and spermidine, putresine. These are the key regulators in placental angiogenesis, 
embryogenesis and trophoblast growth. 
The role of swallowed carbohydrates as well as lipids in AF is less well defined. 
Fetal growth restriction reversal by infusion of nutrients into the amniotic 
environment has not yet demonstrated in studies. 
GROWTH FACTORS  
Human fetal intestinal cells have been cultured to study and demonstrated the trophic 
effects of amniotic fluid(24).Similar to the growth factors present in human milk, the 
growth factors that are present in amniotic fluid plays a vital role in fetus growth and 
development. 
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 The trophic mediators in amniotic fluid  include : 
1.Epidermal Growth Factor(EGF) 
2.Transforming growth factor beta-1(TGF-b1) 
3.Granulocyte colony-stimulating factor (G-CSF) 
4.Erythropoietin 
     Epidermal growth factor (EGF) – this factor peaks  during the mid trimester. In 
fetal growth restriction, this factor is significantly reduced. Its entire function in 
human fetus is still under study and remains unknown yet. 
    Transforming growth factor beta-1 (TGF-b1) – present  in the amniotic fluid 
mainly during the last trimester. This factor plays a role in inducing terminal 
differentiation of the intestinal epithelial cells and also in accelerating the healing 
process of intestinal wounds by inducing cell migration. It also stimulates production 
of IgA(25). 
The entire neonatal gut comprises of Insulin-like growth factor 1 (IGF-I) and IGF-II 
receptors(26). 
     Granulocyte colony-stimulating factor (G-CSF) :studies have come out with 
extensive growth of intestinal cells in sucking mice, when this factor was 
administered enterally. 
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     Erythropoietin: Is present in amniotic fluid, mature milk as well as in colostrum. 
The function of  swallowed erythropoietin in human fetus is not yet clearly 
understood. Its concentration in amniotic fluid is related proportionally with increased 
umbilical cord blood erythropoietin concentration, and hence increased amniotic fluid 
erythropoietin is indicated as a marker for chronic hypoxic status of the fetus(27). 
IMMUNE FACTORS 
Many substances that represent the immune system has been found in amniotic fluid 
and vernix. They have also been found to posess antimicrobial property. 
They include: 
1. The human beta defensin 
2. alpha defensin (HNP1-3) 
3. Lactoferrin (LF) 
       The human beta defensin – represent a major portion in the family of natural 
antimicrobials in vertebrates. Human beta defensins 1-4 are present at mucosal surface. In 
addition, they have chemo attractant properties and  they have also found to have  
interaction  between the adaptive and innate immune system. It functions as a chemokine 
which is involved in parturition. 
Few other antimicrobial agents like alpha defensin (HNP1-3), whose concentrations 
have been increased  in the amniotic fluid in conditions like preterm labour, 
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chorioamnionitis and premature rupture of membranes are probably because of its release 
from neutrophils. 
Lactoferrin (LF), a glycoprotein which has two sites for binding for ferric iron 
appears in human amniotic fluid as early as 20 weeks of gestation. Its concentration rises 
as with gestation. It is found to be secreted in the amniotic fluid by amniotic cells and 
neutrophils.  
Lactoferrin possess both bacteriostatic as well as bacteriocidal activity. It exerts its 
bacteriostatic action by sequestrating iron thereby making it unavailable to aid in growth 
of microbes. Its bactericidal action is exhibited by binding over the outer membranes of 
the bacteria and triggering the release of liposaccharides. Lactoferrin releases a 
microbicidal cationic peptide by the action of enzymes at acid pH called Lactoferricin. 
Lactoferricin exhibits microbicidal action against protozoa , virus and fungi. With the 
onset of labour, lactoferrin levels decreases. 
Other high potent antimicrobial agents exhibiting broad spectrum activity against 
viruses, bacteria, fungi and protozoa  present in amniotic fluid are calprotectin, secretary 
leukocyte protease inhibitor, psoriasin, and  cathelicidin(28,29,30). Certain polyamines 
present in Amniotic fluid possess a cationic charge and has a role in both antimicrobial 
and nutritive value. 
Cellular innate immune system: Mononuclear phagocytes (ie., 
monocytes,histiocytes, and macrophages) in the amniotic fluid are found to be limited in 
normal pregnancies,whereas they are increased in fetuses with multi neural tube defects.It 
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is still uncertain that  these macrophages are present in order to  prevent infection due to 
disruption of fetal skin or behave as scavenger cells to clean the neural debris . 
Neutrophils when present in amniotic fluid, indicates the possibility of infectious foci 
in the amniotic fluid as these are not normally present in the healthy fetuses. 
 
 
FETAL CELLS: 
Amniocentesis is a popular invasive diagnostic technique performed prenatally for 
diagnosing choromosomal and genetic abnormalities. In this procedure, amniocytes and 
the fetal cells that are shed from the skin, gut and genitourinary system along with 
biochemical substances are removed and analyzed. 
PARTICULATE MATTER: 
In the third trimester, the term ‘echogenic amniotic fluid' represents the evidence of 
vernix caseosa or meconium. Pulmonary surfactant produced by the type 2 alveolar cells 
induces a ‘roll up’ phenomenon where it detaches the vernix caseosa from the surface of 
fetal skin. Certain congenital anomalies  have been found to be associated with presence 
of  particulate matter in amniotic fluid. These include 
 fetal acrania 
 harlequin icthyosis  
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epidermolysis bullosa fetalis. 
STEM CELLS: 
Amniotic fluid constitutes different cell types derived from the developing fetus. It 
also includes the cells that are potent to get differentiated to adipose, bone, muscle and 
neurons. 
      Thus stem cells derived from Amniotic fluid are pluripotent and are found to possess 
the ability to differentiate into a huge number of lineages including those that are present 
in all three embryonic germ layers(12,13). 
Amniotic fluid stem cells are said to have all  biophysical characteristics of both adult 
and embryonic stem cells Therefore they are advantageous over both adult and 
embryonic stem cells: 
1. Easily  accessible 
2. Replicates rapidly in culture as they double every 36 hrs 
3. Does not require support from other feeder cells which will   cause contamination 
4. Does not form tumours in vivo 
Amniotic fluid stem cells also possess therapeutic properties(14) and behave as  
precursors to a wide range of differentiated cell types. It has been evident from studies 
that amniotic fluid stem cells can be engaged in repairing damaged tissues from 
conditions like cartilage damage, spinal cord injuries, stroke and diabetes. 
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OLIGOHYDRAMNIOS  
 According to Literature, incidence of oligohydramnios are varied from 0.5% to > 5%, 
depending on the definition of oligohydramnios and study population. As development of 
lung and limbs require adequate amniotic fluid, oligohydramnios possess a negative 
impact on that development. 
Oligohydramnios is found to be associated with 
• pulmonary hypoplasia 
•  postural deformity 
•  fetal distress  
• perinatal morbidity and death. 
 
DEFINITION: 
Oligohydramnios is defined as amniotic fluid volume less than expected for 
gestational age. Amniotic fluid volume measuring less than 500 ml at 32 to 36 weeks of 
gestation is oligohydramnios. 
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Amniotic fluid volume depends mainly on the gestational age, therefore the best 
definition could be the one that is less than fifth percentile. 
Oligohydramnios is defined by USG as an amniotic fluid index 5 cm or less or Singe 
deepest pocket (SDP) of amniotic fluid value less than 2 cm is oligohydramnios. 
 
ETIOLOGY: 
The leading causes of oligohydramnios varies according to the trimester. 
FIRST TRIMESTER: The etiology of oligohydramnios in the first trimester is ill 
understood. It is diagnosed when the difference between the mean sac diameter and the 
CRL is less than 5 mm. At this gestation, the fluid is contributed almost entirely by 
diffusion through the placental surface of the membranes. While this has been seen as a 
sign of poor prognosis, strong evidence is not available in large studies. These 
pregnancies should be followed up to the second trimester before any clinical decision 
can be made. Severe oligohydramnios/anhydramnios in the first trimester, carries a 
uniformly unfavorable diagnosis. 
FIG 5: AMNIOTIC FLUID IN USG IN FIRST TRIMESTER 
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SECOND TRIMESTER: In the 2nd trimester, fetal urine contributes to the 
amniotic fluid volume significantly. Renal abnormalities hence form an important 
etiology. The causes can be sub classified as due to fetal, placental and maternal causes. 
a) Placenta and Membranes: Utero placental insufficiency which causes early 
onset IUGR can result in oligohydramnios. The severity and onset depends on 
the degree of dysfunction and the fetal adaptation. Preterm prelabour rupture of 
membranes(PPROM) contribute to one third of the cases according to one 
study. 
 
b) Fetal : The commonest problem being bilateral renal agenesis which presents 
as anhydramnios as early as 15-16 weeks. In conditions of unilateral renal 
agenesis, liquor volume is maintained normally. Problems occur when there is 
an insult to the solitary functioning kidney which may be in the form of cystic 
renal dysplasia or pelviureteric junction obstruction. Problems of lower urinary 
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tract namely, bladder outlet obstruction due to posterior urethral valve and 
urethral atresia can cause oligo/anhydramnios.  
The timing of onset may vary. Aneuploidy accounts for 8% of the cases. 
Multisystem anomalies account for the rest. Diagnostic procedures like 
amniocentesis or therapeutic procedures for multiple pregnancies involving 
fetoscopy can also cause oligohydramnios due to PPROM 
 
c) Maternal : Maternal systemic disorders including chronic hypertension, 
nephropathy and connective tissue disorders can result in reduced liquor 
volume, secondary to placental insufficiency and IUGR. Maternal drug intake 
mainly, NSAID’s and anti hypertensives (Angiotensin receptor blockers – 
ARB’s) have been proved to cause oligohydramnios or even anhydramnios due 
to renal dysfunction. 
 
FIG 6: AMNIOTIC FLUID IN SECOND TRIMESTER 
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THIRD TRIMESTER : Oligohydramnios in third trimester, is predominantly due 
to PROM. Fetal growth restriction can result in oligohydramnios as detailed above. Many 
cases of third trimester oligohydramnios are due to idiopathic causes. Feldman et al in a 
study in 2009, determined that oligohydramnios is more common in summer months due 
to reduced maternal hydration. 
FIG 7: AMNIOTIC FLUID IN THIRD TRIMESTER 
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DIAGNOSIS: 
        There are no specifc symptoms. Some of the pointers may be H/O leaking per 
vaginum, post term pregnancy, preeclampsia, drugs and less perception of fetal 
movements. On clinical examination the uterus may be small for date ie. Smaller 
symphysio fundal height and feels full of fetus because of scanty amniotic fluid. There 
can be malpresentations and IUGR. 
 
ASSESSMENT OF AMNIOTIC FLUID BY USG 
   Ultrasound measurement of amniotic fluid can be assessed either as subjective 
assessment or as a semi quantitative method. Semiquantitative methods include  single 
maximal vertical pocket (SVP), the two diameter pocket technique and the amniotic fluid 
index (AFI)(3,4). 
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FIG 8: ASSESSMENT OF AMNIOTIC FLUID 
 
 
 
 
 
 
 
 
 
 
 
SINGLE DEEPEST VERTICAL POOL: In the Single Vertical Pool method, 
the deepest vertical pool is identified and then the transducer is placed 
perpendicular to the  contour of the uterus. The maximum vertical diameter of the 
amniotic pool devoid of cord and fetal parts is measured. It is important that at this 
level, the horizontal component of the pocket should be more than 1 cm. 
36 
 
                   FIG 9:SINGLE DEEPEST VERTICAL POOL IN USG 
 
 
 
 
 
 
 
 
 
The interpretation of the SVP is as follows(3): 
• Oligohydramnios -  depth <2 cm 
• Normal-  depth ≥ 2 cm and < 8 cm 
• Polyhydramnios-  depth ≥8 cm 
AMNIOTIC FLUID INDEX(AFI) : AFI is a 4 quadrant method wherein the 
uterus is divided into 4 quadrants by a horizontal and vertical line intersecting at the 
umbilicus. The single deepest vertical pool is measured in each quadrant and the sum of 
all the four quadrants in cms. This technique is used in late second trimester and in the 
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third trimester and not used in early first and early second trimester as the fundal height 
does not cross the umbilicus. The interpretation of AFI is as follows(3) 
• Oligohydramnios: AFI≤ 5 cm 
• Normal: AFI >8 cm and < 20 cm 
• Polyhydramnios: AFI ≥24 cm 
An AFI of 5.1 – 8 cm may be considered as Borderline Oligohydramnios(4) and AFI of 
21-23 cm may be considered Borderline Polyhydramnios. 
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TWO DIAMETER POCKET TECHNIQUE: This technique involves 
measuring and multiplying the vertical and horizontal diameter of a pocket which is 
devoid of cord or fetal parts. The interpretation of this is as follows(5): 
• Oligohydramnios: 0 to 15 cm 
• Normal: 15.1 to 50 cm 
• Polyhydramnios: greater than 50 cm 
There is no agreement in the obstetric literature as to which method of 
sonographic measurement of amniotic fluid volume is best. The investigators concluded 
that the minimal improvement in accuracy offered by another ultrasound measurements 
was not sufficient to warrant replacement of the AFI(6). 
      The upper limit of normal amniotic fluid index is defined a s a value of AFI ≥ 25 cm 
and it can be used for all gestational age and also can be utilized as gestational-age 
specific threshold. Neither method is shown superior to other method(7). 
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COMPLICATIONS: 
FETAL 
• Prematurity 
• Abortion 
• IUFD 
• Potters syndrome- characteristic facies, limb deformities and pulmonary 
hypoplasia 
• Deformities- CTEV, contractures, amputation 
• Malpresentations 
• Cord compression 
• Fetal distress 
• Meconium stained amniotic fluid- Meconium aspiration syndrome 
• Low APGAR 
• Amnion nodosum 
MATERNAL: 
• Prolonged labour- dystocia and uterine inertia 
• Increased operative interference 
• Increased morbidity 
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NEWER CONCEPTS IN MANAGEMENT OF OLIGOHYDRAMNIOS 
 In conditions like fetal obstructive uropathy, where oligohydramnios is commonly 
encountered , as a treatment procedure Vesico-amniotic shunts are found to be quite 
effective in treating low amniotic fluid levels(11). But its effectiveness in  maintaining 
pulmonary and renal functions is questionable yet. 
    L-arginine , a  precursor of vasopressin is a potent treatment option in the treatment of 
oligohydramnios(8)A. 
Newer drugs:  
  Herbal extract of Salvia miltiorrhiza in its purified form have been found to 
improve the amniotic fluid volume in preterm through increasing uteroplacental perfusion 
and circulation. A Chinese medicine, Salvia miltiorrhiza is found to be effective in the 
treatment of oligohydramnios(9). 
The drug hemodialysate(solcoseryl) effectiveness on liquor volume in intra uterine 
growth restriction (IUGR) babies and its outcome in form of APGAR score and health 
status studies concludes that Solcoseryl remains as a drug of choice in pregnancy with 
IUGR,  after 28 weeks of gestation(10). 
MANAGEMENT 
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Depends upon 
• Aetiology 
• Gestational age 
• Severity 
• Fetal status and well being 
Assessment of the pregnant woman with oligohydramnios at term 
A woman with gestational age in between 37-41 weeks with AFI <=5 cm 
1. Look for evidence of ruptured membranes. 
2. Correct her dates. 
3. Order non stress test (NST) to evaluate fetal well being. 
4. Determine presence of hypertensive disorders, diabetes and  conditions leading to 
uteroplacental insufficiency. 
5. Order USG for IUGR and fetal congenital anomalies. 
 
 
  
 
 
 
Any abnormalities revealed in any of 
these tests Induce labour 
Adequate maternal hydration. 
Measurement of AFI  in 2-6 hrs. Is the 
AFI < 5? 
Consider inducing labour 
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TREATMENT 
•  Improve Hydration- plenty of oral fluids 
• Adequate rest 
• Hydration – Oral or IV hypotonic fluid (2 litres/ day) 
    - Temporary improvement 
    - Betterment  during labour,  just prior to ECV and USG 
• Serial Ultrasound – to monitor growth,BPP, AFI 
•  LSCS or Induction of labour depends  upon 
- Lung maturity status 
- Lethal anomalies 
- Severe IUGR 
- Severe oligohydramnios 
 
 
 
 
Is the AFI 5-8?  Measure the AFI again in 3-4 days 
Is the AFI is >8, perform AFI 
measurement and NST weekly 
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AIMS AND OBJECTIVES 
To determine Obstetric outcome in term low risk pregnancy with AFI less than or 
equal to 5. 
To assess whether antepartum oligohydramnios is associated with adverse 
perinatal outcome. 
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REVIEW OF LITERATURE 
  Oligohydramnios is a frequent complication of  pregnancy that is found to be 
associated with a bad perinatal outcome. Etiologies include premature rupture of 
membranes (PROM),congenital anomalies, intrauterine growth restriction (IUGR), post 
datism, drugs, abruptio placentae, twinning abnormality, severe maternal illness and 
idiopathic oligohydramnios. 
 Prolonged oligohydramnios leads to pulmonary hypoplasia and fetal compression 
syndrome. Perinatal morbidity and mortality are significantly increased in pregnancies 
with oligohydramnios.  Ultrasound finding of oligohydramnios should remind the 
clinician to evaluate the patient for other significant illness. 
 Further a thorough fetal anatomic study highlighting on the genitourinary tract and  
looking for free amniotic bands should be done with ultrasound. Karyotyping plays an 
important role.  
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 Once diagnosed, oligohydramnios, should further lead to intensive fetal  
surveillance including ultrasound evaluation. The role of amnioinfusion as a support to 
continuous fetal monitoring in labour to improve neonatal outcome appears beneficial in 
selected study series.  
 David G. Weismiller(31);  Said the two most common uses of transcervical 
amnioinfusion are dilution of thick meconium fluid during labour and treating 
decelerations.  In 1983, Hill-LM(32); et al  concluded that oligohydramnios remains as an 
important factor for intrauterine growth restriction and has been studied in populations 
prone to have IUGR. They studied the incidence in obstetric population. During 16-
months of study period, USG scans were done in 1,408 patient. Severe oligohydramnios 
were found in six patients (0.43%). Two of them found to have congenital malformations, 
4 were found to have severe IUGR. A subgroup of 317 patients who were scanned within 
2 weeks of confinement was then reviewed. Although none of the patients fitted the 
proper criteria of oligohydramnios (absence of a pocket of amniotic fluid 2 cm or less in 
largest diameter), three of six small-for-gestational age infants, had a subjective decrease 
in amniotic fluid volume for their respective gestational age. By changing the criteria of 
oligohydramnios to a subjective decrease in amniotic fluid volume, the sensitivity of 
ultrasonic marker was increased by 50% and the specificity by 100%. They found out 
that the semiquantitative assessment of amniotic fluid volume can be used to effectively 
screen for IUGR, regardless of  gestational age, at risk for perinatal morbidity and 
mortality. 
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         Eighty pregnancies encountered by oligohydramnios forms the basis of a 
retrospective study done by (33)Shenker-L et al.  Forty patients had PROM ; of which 24 
had good outcome. Twelve of 14 fetuses with oligohydramnios and IUGR had good 
survival rate. None of  nine fetuses with renal anomalies were alive. None of the twin 
with twin to twin transfusion syndrome and oligohydramnios lived. Six pregnancies with 
premature separation of  placenta and with oligohydramnios were identified; all of them 
resulted in fetal or neonatal death during the (10) second trimester.  
      William-K(34), said amniotic fluid measurement plays a very important role in 
assessing fetal well being because it has an advantage of being non invasive. Uterine 
cavity being not regular is difficult and complicated to find indirect techniques.  
  The three ultrasound methods include 
 1)assessment of the subject 
2) maximum vertical pocket depth  
 3) amniotic fluid index (AFI).  
 All three techniques aid in  predicting  peripartum mortality and morbidity by 
measuring amniotic fluid volume. 
 Amniotic fluid volume (AFV) remains a good predictor of perinatal outcome 
when used in combination with fetal biophysical profile to determine perinatal outcome.  
 Youssef AA, et al(35); quoted semiquantitative Amniotic fluid volume 
determination is one of the component of fetal biophysical profile . TO determine 
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reduced AFV they performed BPP for 174 fetuses with in one week of confinement. Two 
techniques was used,one by measuring  single  vertical pocket depth (oligohydramnios  
<1cm) and 4 quadrant AFI (AFI <5cm). AFV,  studied by each technique were associated 
with  fetal outcome measures (meconium stained amniotic fluid, fetal distress, IUGR, 
lower Apgar score and perinatal morbidity ).  
 The AFI remains highly sensitive in predicting mortality (87.5%) and also other 
measures of perinatal morbidity: fetal distress amounting to 86.6%, meconium stained 
fluid to 63.6%, low 5-minute Apgar score to 88.8% and  IUGR  with 79.4%. The 
sensitivity of AFI  <1cm was 72.2%, 66.6%, 75% and 55.8%, respectively for the 
respective  measures.  
 Their study data determines that qualitative measurement of AFV using AFI 
remains better to that of single vertical pocket in fetal biophysical surveillance. In 1989, 
sixty-two cases of olighydramnios diagnosed by ultrasound between 13-28 weeks (12) 
gestations were reviewed by Three Moore-TR et a(36)l; skilled ultrasonographers rated 
oligohydramnios into grades of mild, moderate, severe, or nil. Inter observer views were 
excellent. The overall  incidence of pulmonary hypoplasia  was 33% and perinatal 
mortality were 43%. One-third found to have fatal congenital anomalies. The severity of 
adverse outcome corelated severely with severe most degree of oligohydramnios; with 
only 11 % in mild and moderate group and 88% with severe oligohydramnios or 
anhydramnios underwent adverse outcomes. The presence of urogenital tract anomaly 
was associated with the  severe degree of oligohydramnios and remained fatal . 
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Pulmonary hypoplasia was found evident in 6% of the moderate group and  60% in the 
severe group. 
 They came to a conclusion that subjective grading in oligohydramnios by skilled 
observers remained both predictive and reliable of perinatal outcome. The evidence of 
severe oligohydramnios in second trimester was strongly predictive of adverse fetal 
outcome as it necessitates a thorough search for etiology and prompt intervention. 
Moderate grades of decreased amniotic fluid may be managed with  optimistic attitude.                         
         In1986 Sivit CJ; et al(37)  reviewed  ultrasonograms of all patients with 
oligohydramnios between 16 and 30 weeks of gestation over a period of 4 years to 
understand:- 1- Whether sonographically identified fetal anomalies were present.  2- 
When these anomalies been present, how could this information be used in managing 
maternal and fetal outcome. Cases of fetal demise and ruptured membranes were 
excluded from the study. 
         Sixteen patients with severe oligohydramnios was identified. On postmortem 
examination, nine were found to have urinary tract anomalies, one with evidence of 
chronic intrauterine infection, and four with no anomalies. Only two neonates survived: 
one had no anomaly while the other had posterior urtheral valve. These findings 
concluded that second trimester oligohydramnios had poor prognosis and were often 
related with anomalies of urinary tract. Sonography helps in the clinical management of 
those patients.  
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       Outcome of structural pathology was studied in 170 chromosomally abnormal fetus 
by Wladimiroff JW(38), referral for those before 20 wks gestation was based only fetal 
structural pathology  (92%); after 20 wks patients  referral was based on structural 
pathology combined with small for gestational age polyhydramnios/oligohydramnios.An 
abnormal AFV were  present in 59 out of 170 (34.5%) chromosomally affected 
pregnancy i.e. polyhydramnios in 28 and  oligohydramnios in 31 cases with adverse fetal 
outcome.  
       Mercer-LJ; Brown LG(39)  diagnosed 34 cases of oligohydramnios in  2nd trimester 
in ultrasound scan. 9 of of those pregnancies was associated with fetal anomalies like 
atrioventricular dissociation (two), Potter syndrome (three),  multiple anomalies (three) 
and congenital absence of thyroid (one). There was ten unknown stillbirths, only one fetal 
demise due to abruptio placentae, eight with perinatal morbidity after preterm labor 
and/or abruptio placentae, and six were live- born  full term infants. Although 
oligohydramnios in the 2nd trimester were found to be  associated with high perinatal 
morbidity, this finding was not associated with  poor outcome universally. 
       In 1997,eighteen cases with bladder outlet obstruction was diagnosed (40) at Queen 
Mother’s Hospital  for a 6 yr period. Commonest cause found to be was posterior urtheral 
valve observed in 11 cases (61%) oligohydramnios was present in 78%of patients with 
mortality of (67%) mainly due to pulmonary hypoplasia. The six survived infants (33%) 
underwent early postnatal surgery. Two of these were found to develop chronic renal 
failure on further follow up. 
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     Levine-D; et al(41);  said preterm fetuses with breech presentation had more incidence 
of dolichocephaly than with the ones who had cephalic presentation and it was more 
common in oligohydramnios with longer duration.  10 out of 12  living dolichocephalic 
fetuses with cephalic presentation developed respiratory distress syndrome compared 
with 31 of 73 (42%) in normocephalic fetuses. They concluded that dolichocephaly was 
found to be associated with oligohydramnios of prolonged duration .In fetuses with 
preterm rupture of membranes, it is associated with respiratory distress syndrome.                                 
       In 1984 Barss-VA(42); et al reported 12 cases of severe oligohydramnios in second 
trimester. The outcome of those pregnancies were poor all throughout, with no survivors 
in the entire series. Of them, Four patients had therapeutic abortions, one of them 
underwent spontaneous labor at 22 weeks, and seven of them continued till viability. Of 
these, around five patients were found to have severe renal anomalies that were not 
compatible with life .Two infants died near or immediately after, birth due to severe 
intrauterine growth retardation (IUGR), one had a triploid karyotype. Review of the 
literature showed a similar adverse outcome with severe oligohydramnios in the 2nd 
trimester. 
      Wolff-F et al(43) studied complications in oligohydramnios  in past medical records, 
Of all 5,210 of deliveries between 1987 and 1990, 181 cases with oligohydramnios were 
studied. The diagnosis was  by USG and was based on the  method described by Plat and 
Mannings: Amniotic fluid pockets of <1cm were defined as oligohydramnios.All of 181 
meet the above definition, that resulted in an incidence  3.5% pregnancies with decreased 
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amniotic fluid. They reviewed the records of both fetus and the mother, the delivery and 
its perinatal complications and the follow up of newborn. In more than 60% fetal 
asphyxia, breech presentation and other abnormalities during delivery lead to Cesarean 
section and vaginal operative delivery by application of forceps or vaccum extraction. In 
30 cases, oligohydramnios were found to be caused by PROM. In the  remaining cases,  
diagnosis was based on fetal and maternal complication such as abruptio placentae (n=10, 
multiple gestation (n=7),), fetal growth retardation , and malformations or chromosomal 
anomalies. Eighty-nine newborns was referred to a children’s hospital after delivery. 
Potter’s syndrome was the most anticipated diagnosed malformation (n=20). The 
decreased amniotic fluid was further more followed by a high rate of respiratory 
complications such as hypoplasia of the neonatal lung (n=21) and Respiratory Distress 
Syndrome. 
        In conclusion, their study highlighted that oligohydramnios should be considered as 
marker of high risk pregnancy followed by other complications of fetus and newborn 
.The incidence of perinatal mortality in their study was 7.2%  and this rate was found to 
be 10 fold higher compared to total number of the deliveries in their department. 
        Golan –A; et al(44) diagnosed 145 cases of oligohydramnios in  2nd &3rd trimester  
by ultrasonogram  out of 25,000 obstetric patients amounting to 0.58%. In that group,  
common complications encountered are induced hypertension in 22.1% and bleeding in 
the 2nd trimester in 4.1%. There was a high incidence of meconium-stained amniotic 
fluid in 29.1% fetal distress in 7.9% and premature separation of placenta in 4.2% IUGR 
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(24.5%) . Asphyxia during labour was encountered  in (11.5%) and many other perinatal 
problems in (23.5%). Cesarean section were performed in 35.2% of those pregnancies, 
17% of  cases presented by breech. IUFD were in (5.5%) of those pregnancies. The 
overall perinatal mortality amounted to (16%) and the corrected perinatal mortality 
amounted to 10.7%. The overall fetal malformations was in 11% & that fatal 
malformations were in 4.8%. The urinary system (4.1%) and skeletal (7.6%) were the 
systems affected. Oligohydramnios was associated with increased rate of fetal morbidity 
and mortality, thus termination must be decided in case of fetal distress. 
          In 1990 Lin-CC; et al(45) studied  147 cases of suspected IUGR  based on 
ultrasonographic abdominal  circumference below  10th percentile, 56 were confirmed as  
IUGR infants. Eight of 316 control fetuses with abdominal circumference above the 10th 
percentile figured out to be IUGR infants at birth. The incidence of oligohydramnios was 
stunningly different among the other three groups: 29% for  IUGR group, 9% for non-
IUGR group and 0.6% for the control group (P less than 0.001). When the same criteria 
of abdominal circumference below the 10th percentile & the presence of 
oligohydramnios were combined together, the positive predictive value seemed to be 
doubled (from 38.1 to 66.7%; P less than 0,01). Finally there was no significant 
difference between fetal growth retardation with or without oligohydramnios, in respect 
to maternal high risk factors or the fetal outcome. They confirmed that in fetal growth 
retardation, the occurrence of oligohydramnios during the 3rd trimester of pregnancy was 
not strongly associated with adverse fetal outcome.   
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       In study done by Conway-DL(46); et al  women who underwent labor induction for 
isolated oligohydramnios between 37 to 41 weeks of gestation were counter matched by 
gestational age and  parity to women with normal AFI who presented in spontaneous 
labor. Pregnancies complicated by hypertension, diabetes, fetal anomalies, or suspected 
IUGR were excluded. The primary outcome variable was mode of delivery. Secondary 
outcomes examined were presence of meconium, acidosis, low Apgar score and NICU 
admission. A total of 183 women underwent induction for isolated oligohydramnios. 
When compared to the control group, neonatal outcome had no difference in the group 
induced for oligohydramnios. However the women who were induced had significantly 
more Cesarean section deliveries (15.8% vs. 6.6%, P<0.01, odds ratio 2.7). They 
concluded that  isolated oligohydramnios in  otherwise normal term pregnancy might not 
be a marker for fetal compromise; an induction of labour might not be warranted in most 
cases.  
        Hsich TT et al(47) ;  investigated the perinatal outcome of patients with 
oligohydramnios (AFI <5cm) but excluding PROM and  congenital fetal malformations, 
data from (245) singlet pregnancies were thoroughly investigated and compared with 
normal AFVs (5<AFI <24 cm n=27, 261).High incidences of primigravida, premature 
separation of the placenta, past history with IUFD, past history of preterm, post term 
pregnancy and advanced maternal age were noticed to occur with oligohydramnios. 
Pregnancies complicated by severely diminished AFV identified antenataly by 
ultrasonogram were more frequently associated with adverse perinatal outcomes such as 
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preterm delivery, low/ very low birth weight, low Apgar scores, IUFD, SGA newborn, 
meconium stained amniotic fluid, C/S delivery and neonatal death. Indomethacin is a 
non-steroidal anti-inflammatory agent widely used in the treatment of premature 
contractions. Indomethacin-induced oligohydramnios is a well documented side effect, 
and is strongly recommended as an indication for treatment discontinuation. 
        Shen-O, et al(48)  presented a case of prolonged anhydramnios, secondary to 
indomethacin therapy with no apparent ill effect on the fetus or neonate. (49) Los-FJ et al 
stated early 2nd -trimester oligohydramnios were associated with normal levels of 
maternal alpha-feto protein (MSAFP)  in 9 out of twenty six cases (35%) of congenital 
malformations of  fetal urine tract that resulted in anuria was found to present in 9 cases; 
of which 7  being normal  MSAFP level, were measured . Whereas, normal (MSAFP) 
level, was present in 2 out of  17 cases with no fetal malformations. These  suggests that 
the fetal urine contributes the source of elevated AFP in the  maternal compartment in the 
early 2nd –trimester with oligohydramnios. This is supported by lack of relation-ship 
between concentration of MSAFP  with concanavalin A, created from AF pool  (AFP), 
and its  presence of fetal diuresis . 3  of 26 women had early recurrent risk of this  
condition. 
       Sarno-AP(50); et al  studied  200 term gravidas  who  presented in the latent phase of 
labor with vertex- presenting fetuses. An intrapartum AFI <5cm was associated with 
significant increase in  Cesarean section in view of fetal distress and an Apgar  score of 
<7 at one minute and abnormal fetal heart rate  , the majority (71.4%) of the patient with 
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an intrapartum AFI <5cm had ruptured membranes on their admission; but, there was no 
profound significant difference found in outcome when they were compared to patients 
with intact membranes and oligohydramnios. Variable decelerations on admission were 
associated with oligohydramnios in (43.8%) of the patients. An AFI <5cm in their 
intrapartum period is a major risk  for perinatal morbidity & abnormal fetal heart rate 
patterns in labor, and ruptured membranes in early labor are risk factor for 
oligohydramnios.                             
        Sadovsky-Y(51), et al tested the hypothesis that patients who have a large cord- 
containing AF pocket has a lower risk for adverse perinatal outcome than women with 
small cord –containing AF pocket . Gravidas with an antepartum AFI not > 5 cm were 
thoroughly studied prospectively. The vertical diameter of the single largest cord- 
containing pocket, which was excluded from the calculations of the AFI, was measured. 
Women of ruptured membranes, multiple gestation, or fetal anomalies were excluded. 
Results of 51 women with gestational age of 35- 43 weeks were analyzed. Among 35 
who had a cord –containing pocket of no > 5cm, 8(23%) had fetal distress demanding 
operative delivery and eight neonates had cord arterial PH below 7.2. None of these 
complications occurred in the16 women who had cord-containing pocket more than 5 cm 
(P <0.05). The mean AFI (2.9 versus 2.8 cm ) was not significantly different between the 
groups. Conclusions: Among women with a low AFI, cord – containing pocket above 
5cm identified a subset of women at lower perinatal risk  compared with those with 
smaller cord-containing pocket.   
56 
 
         Van-Reempts P(52); et al  studied  outcome of neonates  after very prolonged 
premature rupture of membranes (VPPROM) in 3 categories of  neonates  who were born 
before 34 to  52 weeks of gestation: group (1) VPPROM with oligohydramnios (n=14);, 
group (2) VPPROM without oligohydramnios-(n=28); and group (3), the comparison 
group without VPPROM (n=39).  Mortality in the group (1) (2 of 28 ) was similar to that 
in group (2) (6 of 39 ) and was lower than that in group (2) with 5 of 14. Lung hypoplasia 
and the limb deformities does not occur frequent in group (1) than in group (3) ( 2of 28 
and 0 of 28 versus 3 of 39 and 1 of 39 respectively) but occurred more frequently only in 
group (2) (5 of 14 and 4 of 14 ).  All deaths in group (1) and (2) were because of lung 
hypoplasia. There were no significant difference between  groups for asphyxia, (air leaks, 
respiratory distress syndrome, intracranial bleeding or bronchopulmonary dysplasia. 
Neonatal infection were more frequent in group (1) (4 of 14, 28.6%) and group (2) (7 of 
28, 25%) when compared with group (3) (2 of 39 = 5%).  Within groups (1) & (2) rupture 
of  membranes were not very prolonged in neonates with infection (median, 9.7 days) 
compared with the neonates without infection (with a median, 9.6 days). They concluded 
that VPPROM is not complicated by oligohydramnios, mortality from lung hypoplasia 
and limb deformities were not found more frequent than in control (29) neonates of 
similar gestational age. 
      Bastide –A(53); et al ; defined  severe oligohydramnios where the largest pocket of 
amniotic fluid  measures <1cm in its  vertical dimension as determined by the USG, was 
studied in 113 patients  in a population of  15, 431 referred as high risk patients (0.7%). 
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In all cases, intervention was done unless there were a recognized structural anomaly or 
extreme prematurity. Overall  perinatal mortality was 132.7/1000, and the incidence in 
major anomaly was 13.3%. The corrected perinatal mortality rate was 17.7/1000 with 
intervention, a rate that was insignificant from that the rate observed in  entire population. 
These findings were interpreted to emphasize that severe oligohydramnios in structurally 
normal (30) fetus remains  an indication for deliver. 
       Van-Dongen-PW(54); et al did a study retrospectively to detect the frequency of lethal 
lung hypoplasia in 48 cases with prolonged rupture of membranes for > 7 days before 34 
weeks’ gestation.  Fourteen infants died amounting to 29%, but only four deaths in 8.3% 
was died due to lung hypoplasia. Three infants with lung hypoplasia had their membranes 
ruptured before 20 weeks gestation and showed presence of a  persistent 
oligohydramnios, one with rupture  at 26 weeks. The duration of rupture of membranes 
nor the gestational age at the time of rupture showed no influence in the occurrence of 
lung hypoplasia. 
       Schrimmer-DB(55); et al studied prophylactic amnioinfusion as one of the  treatment 
of oligohydramnios in a randomized study with a sample of 305 patients with 
oligohydramnios in labour, 175 patients underwent amnioinfusion and the remainder 
served as controls. Amniotic fluid was titered to  AFI >10 cm in treatment group. Patients 
who received amnioinfusion had significantly less operative interference for fetal distress 
(P =0.0001) and few C/S (P =0.0001). Umbilical artery PH  was also increased (P = 
0.0001). Rates of amnionitis and endometritis were insignificant in infused patients and 
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controls.Though the hospital stay was markedly decreased (P= 0.002) in the treatment 
group, their data had support of earlier reports that amnioinfusion serves as technique for 
reducing intrapartum morbidity for both fetus and the  mother (32).                                                       
       Strong TH(56), et al performed amnioinfusion in a  randomized trial of sixty women 
in  latent phase  with oligohydramnios by AFI < 5cm. All fetuses were at 37 weeks 
gestation, having a  normal baseline fetal heart rate variability and no clinically 
significant fetal heart rate decelerations. The amnioinfusion group (n=30) were 
maintained at AFI level  > 8.0 cm through the labor .In the group who received 
amnioinfusion, passage of meconium was exhibited in lower rates(p=0.04), operative 
delivery for fetal distress (P=0.002)and end stage bradycardia (P=0.05) occurred. 
Significant high umbilical arterial blood PH values was noticed in  infusion group 
(P=0.02). They came to a conclusion that prophylactic intrapartum amnioinfusion serves 
as a valuable technique in reduction of morbidity.                                                                                       
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MATERIALS AND METHODS 
Present study was conducted at Chengalpattu Medical College in Department of 
Obstetrics and Gynaecology over period from 2015 to  2016. 200 patients in third 
trimester attending our hospital with evidence of Oligohydramnios were selected after 
satisfying inclusion and exclusion criteria and studied prospectively. 
INCLUSION CRITERIA: 
1) AFI less than or equal to 5. 
2) Single live intrauterine gestation with cephalic presentation. 
3) 37 completed weeks of gestation. 
4) Intact membranes. 
EXCLUSION CRITERIA: 
1) Gestational age less than 37 completed weeks. 
2) AFI more than 5. 
3)Post term. 
4)Associated fetal malformations. 
5) Malpresentation and multiple gestation. 
6) )Ruptured membranes Malpresentation and multiple gestation. 
7)High risk pregnancy 
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   a)Placental insufficiency 
• Hypertension 
• Preeclampsia 
• Diabetes 
• Chronic renal disease 
• Hypovolemia 
• Connective tissue disorders 
           b)Abruption 
           c)Prostaglandin synthestase inhibitors               
 therapy. 
           d)Angiotensin converting enzyme inhibitors  
  therapy. 
 8)Uterine scar due to Previous LSCS,myomectomy,hysterotomy. 
 Study was conducted in order to observe outcome of labour in the form of 
maternal and perinatal outcome. After collecting a detailed history, complete examination 
was done. All required investigations performed with respect to patients condition. 
Oligohydramnios is confirmed by measuring Amniotic Fluid Index by USG. Routine 
management in form of rest, oral and intravenous hydration, left lateral position and 
control of etiological factor was done if present. Fetal surveillance was done by means of  
modified Biophysical profile and USG . Decision of delivery by  induction or elective or 
emergency LSCS was done as indicated Some patients who were already in labour  were 
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allowed to go in spontaneous labour. Cases were than thoroughly studied to observe 
maternal and perinatal outcome. 
 
OBSERVATION AND RESULTS 
A total of 200 women attending to our institution got admitted and studied in the 
study period. 
Table 1 : AGE DISTRIBUTION 
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Table 2 : MATERNAL OUTCOME OF LABOUR WITH RESPECT TO AGE 
 
 age group Total 
<20 >30 21-25 26-30 
MOD 
LN 
Count 5 1 37 29 72 
      
% within age 
group 
41.7% 33.3% 33.3% 39.2% 36.0% 
LSCS 
Count 7 2 74 45 128 
      
% within age 
group 
58.3% 66.7% 66.7% 60.8% 64.0% 
Total 
Count 12 3 111 74 200 
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% within age 
group 
100.0% 100.0% 100.0% 100.0% 100.0% 
 
Table 1and 2 shows the distribution of study population according to age. 
Maximum patients belonged to  21-25 years. Rate of cesarean was found to be highest in 
the age group of 21-25 years . 
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Table 3 : PARITY DISTRIBUTION AND MATERNAL OUTCOME OF LABOUR 
Out of 200 patients, 120 were primi and 80 were multiparous women. Operative 
delivery were more in primi (66.7%) compared to multipara (60 %). 
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PARITY LABOUR 
NATURAL 
LSCS TOTAL 
 
PRIMI 
 
40 (33.3%) 
 
80 (66.7%) 
 
120 
 
MULTI 
 
32 (40%) 
 
48 (60%) 
 
80 
 
 
    
    
   
   
 
 
 
 
 
 
 
  
 
CTG 
 
REACTIVE 
 
NON REACTIVE 
 
0
20
40
60
80
100
120
140
non react
Table 4: CTG 
 
NUMBER PERCENTAGE
 
72 
 
128 
reactive
FREQUENCY
66 
 
 
 
36 
 
64 
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On observation, 128 (64%) out of 200 patients had non reactive CTG and only 
72(36%) had reactive CTG. Operative morbidity were more in non reactive CTG group. 
Table 5: MODE OF DELIVERY WITH RESPECT TO CTG 
 MOD 
LN LSCS 
REACTIVE 
non react 1 81 
reactive 71 47 
Total 72 128 
P value :0.001 
 
 
 
 
 
 This table shows that the rate of cesarean section was 
CTG group . Its p value is (0.001) and it is statistically significant.
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Table 6: DISTRIBUTION BY AFI( USG) 
 
AFI 
 
FREQUENCY 
 
PERCENT 
 
1 TO 3 
 
12 
 
6 
 
4 TO 5 
 
188 
 
94 
 
TOTAL 
 
100 
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This table shows that 94 % of the study population had an Amniotic fluid index of 
4 to 5 cm and 6 % with AFI 1 to 3 cm. 
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Table 7: MODE OF DELIVERY WITH RESPECT TO AFI 
 
 AFI NO  
Total 
1 TO 3 4 TO 5 
MOD 
LN 
Count 0 72 72 
% within MOD 0.0% 100.0% 100.0% 
% within AFI NO 0.0% 38.3% 36.0% 
LSCS 
Count 12 116 128 
% within MOD 9.4% 90.6% 100.0% 
% within AFI NO 100.0% 61.7% 64.0% 
Total 
Count 12 188 200 
% within MOD 6.0% 94.0% 100.0% 
% within AFI NO 100.0% 100.0% 100.0% 
72 
 
     
 
 
 
This table shows that there was nil Labour natural in the subset of AFI 1 to 2 in the 
study population and Caesarean section rate was higher in this group. 
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Table 8: MODE OF DELIVERY WITH RESPECT TO MECONIUM 
 
 MOD  
Total LN LSCS 
meconium 
NO 
Count 63 20 83 
% of Total 31.5% 10.0% 41.5% 
YES 
Count 9 108 117 
% of Total 4.5% 54.0% 58.5% 
Total Count 72 128 200 
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% of Total 36.0% 64.0% 100.0% 
P value: 0.001 
 
 
Overall meconium stained amniotic fluid occurred in 58.5% of the study population. Of 
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which 36% had labour natural and 64% had cesarean section.It was statistically 
significant (p value <0.001). 
 
 
 
 
Table 9: DISTRIBUTION OF STUDY POPULATION ACCORDING TO BIRTH 
WEIGHT 
  
Frequency 
 
Percent 
Valid 
<2500 16 8.0 
>2500 184 92.0 
Total 200 100.0 
 
 
  
 
Table 10: INCIDENCE OF STILL
 
 
Valid 
NO 
YES 
0
20
40
60
80
100
120
140
160
180
200
<2500
 BIRTH 
 
Frequency Percent
198 
2 
>2500
Chart Title
Frequency Percent
76 
 
 
 
99.0 
1.0 
 Total 
 
 
 
Only 1% still birth was present in the study population.
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Frequency
200 
 
Percent
77 
100.0 
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Table 11: INCIDENCE OF NICU ADMISSION 
 
 Frequency Percent 
Valid 
NO 188 94.0 
YES 12 6.0 
Total 200 100.0 
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This table shows that the incidence of NICU admission accounted to 6% of the 
study population.  
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Table 12 : PERINATAL OUTCOME 
DISEASE NUMBER PERCENT 
BIRTH WEIGHT  
16 
184 
 
<2.5 KG 
>2.5 KG 
8 
92 
 
APGAR SCORE  
36 
 
18 
 
<7 at 1 to 5 mins 
STILL BIRTH 2 1 
 
MECONIUM 117 58.5 
 
NICU ADMISSION 12 6 
 
PERINATAL 
MORTALITY 
4 2 
 
 
 
 The above table shows the overall perinatal outcome with respect to birth weight    
( <2.5 kg-8% and >2.5 kg-92%), Apgar score (<7 at 1
meconium (58.5%)., NICU admission(6%) and perinatal mortality (2%).
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DISCUSSION 
It is a known fact that severe oligohydramnios is associated with adverse perinatal 
outcome. On other hand, it still remains a poor predictor in detecting adverse outcome. 
But often oligohydramnios is used as an indication for operative delivery. Hence 
assessing amniotic fluid volume antenatally is essential in determining high and low risk 
groups. 
  In our study maximum number of women (n= 200) were in the age group of 21 to 
25 years ( n=111). Of which highest percentage of women (120) were primipara and 80 
were multiparous. This was partially evident with that of Jagatia et al.,where they 
reported that incidence of oligohydramnios was more in primipara which is compatible 
with the study of  Petrozella et al and Jandial et al.,  
 The present study revealed that, cesarean section rate was higher among non 
reactive CTG group. This goes with the study by Charu Jandial whish stated  a non-
reactive CTG + AFI< 5 cm indicated fetal jeopardy according to revised Biophysical 
profile scoring by Clerk e al,.The fetal jeopardy reflected an increased operative 
interference in this study. 
 This study showed high incidence of meconium stained liquor( 58.5%) in 
oligohydramnios patient with AFI<5 cm.  Meconium staining is an indicator of fetal 
distress and has its own complication in newborn. This finding is matching with many 
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research studies during various studies of Chandra et al., Sriya et al., Chate et al., and 
Ghike et al. In addition Jandial et al.,observed meconium stained liquor in 48% of women 
with oligohydramnios. Also, Youssef et al., found it in 40% of oligohydramnios group. 
This suggests that there is high incidence of meconium staining in oligohydramnios 
group. 
  The rate of NICU admission was found to be 6 % , of which perinatal mortality 
was 2%. In the study done by Wolff-F, 49.17% of newborns were referred to nearby 
pediatric hospital immediately following delivery. This difference may be due to the 
facilities encountered in the hospital set up. 
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LIMITATIONS OF THE STUDY 
The limitations of  study includes the following:  
1. Only 200 cases were available during the study period which exactly satisfed inclusion 
and exclusion criteria which is less compared to other studies. 
 2. The diagnosis of  fetal distress was made depending on FHR tracings. However, the 
fetal acidosis was not proved by fetal scalp blood sampling or other methods because of  
non-availability 
 3. The use of  backup surveillance methods like scalp blood sampling and acoustic 
stimulation and amnioinfusion would have altered the outcome.  
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RECOMMENDATIONS 
Determination of AFI should be used as an adjunct to other fetal surveillance methods.   
It helps to identify those infants  at risk of having poor perinatal outcome 
It remains as a valuable screening test for predicting fetal distress in labour requiring 
cesarean section in oligohydramnios patient. 
Continuous antepartum and intrapartum monitoring are mandatory for every women 
diagnosed with oligohydramnios to reduce the maternal and neonatal risks associated 
with oligohydramnios. 
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The suggested plan of action: 
Development  of     health     instruction brochure to raise the pregnant women′s 
awareness regarding   oligohydramnios and  its management. 
 2. The    brochure         should         include knowledge related to the definition of 
oligohydramnios  and  its maternal and fetal outcome. 
 3. The  brochure  should  be  distributed  to the pregnant women during their scheduled 
antenatal visit. 4. Meeting with the antenatal clinic nurses to encourage them to educate 
pregnant women about oligohydramnios, its maternal and fetal outcome and its plan of 
action. 
  5. Referral  of     the     women  who  had oligohydramnios  to the proper channels for 
further examination. 
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CONCLUSION 
Oligohydramnios is commonly encountered and it necessitates extensive fetal 
surveillance and perfect antepartum and intrapartum care. Amniotic fluid volume is an 
important predictor of fetal level of tolerance during labour and its decrease is associated 
with increased risk of fetal distress and meconium staining of fluid. Due to unforeseen 
intrapartum complication and high incidence of perinatal mortality and morbidity, 
cesarean section rates are on the rise, but the decision between cesarean section and 
vaginal delivery must be well balanced so that unnecessary maternal morbidity could be 
prevented and timely decision can reduce perinatal mortality and morbidity. 
   To conclude, an AFI measurement of less than 5 cm detected after 37 completed 
weeks of gestation with a low risk pregnancy is found to be an  indicator of adverse 
pregnancy outcome with higher cesarean section rate. 
 In our study, in presence of AFI <5 cm, the occurrence of non reactive CTG, 
incidence of meconium stained liquor and rate of LSCS are high.  
Hence AFI assessment serves as an important tool and remains as an efective 
screening test in predicting fetal distress in labour that requires cesarean section. 
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LIST OF ABBREVIATIONS 
 
IUGR  :             Intrauterine growth restriction                       
 HTN  :             Hypertension                                                  
 PPROM :           Premature prelabour rupture of membranes  
APH  :            Antepartum hemorrhage                                  
CTG  :            Cardiotocography                                          
 C/S  :            Cesarean section                                            
EM/C/S :            Emergency C/S                                              
EL/C/S :             Elective C/S                                                   
 USS  :             Ultrasound scan    
VD  :             Vaginal delivery                                              
SVD  :             Spontanous VD       
NICU  :             Neonatal intensive care unit                           
 PIH  :             Pregnancy induced hypertension                     
Kg  :             Kilogram                                                          
Wt  :             Weight                                                            
 GA  :             Gestational age                                                
 FSB  :             Fresh stillbirth                                               
 MSB  :             Macerated stillbirth                                        
 AFI  :            Amniotic fluid index                                        
AFV  :             Amniotic fluid volume                                     
ACE  :             Angiotensin - converting enzyme                     
Fig  :             Figure                                                                
IUFD  :             Intrauterine fetal death                                      
MSAFP :             Maternal serum alpha-feto protein                  
 PG  :             Phosphatidyl glycerol     
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INFORMATION SHEET 
 We are conducting a study on “Outcome of pregnancy and perinatal outcome in 
Amniotic Fluid Index less than or equal to 5 in term low risk pregnancy” 
 The purpose of the study is to find whether antepartum oligohydramnios is 
associated with adverse perinatal outcome and to determine Obstetric outcome in 
low risk term patients with AFI less than or equal to 5. 
 The privacy of the patient in the research will be maintained throughout the study. 
In the event of any publication or presentation resulting from the research , no 
personally identifiable information will be shared. 
 Taking part in the study is voluntary. You are free to decide whether to participate 
in this study or to withdraw at any time. Your decision will not result in any loss 
of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
Signature of investigator                           Signature of patient /guardian 
 
Date : 
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NO NAME AGE PARITY NUMBER GA  AFI NO AFI REACTIVE 
mecon
ium FHR IUGR 
INDICATI
ON MOD 
STILL 
BIRT FETAL DIS B.WT APGAR1 
APGAR
5 
NICU 
adm 
perinat 
mo 
1 tamil 22 multi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
2 Rosi 27 multi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
3 subadra 26 primi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.9 NORMAL 
NORM
AL NO NO 
4 anandi 20 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 3.2 NORMAL 
NORM
AL NO NO 
5 hema 24 primi 1 37 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 3 NORMAL 
NORM
AL NO NO 
6 madhavi 25 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
7 princy 23 primi 2 38 1 TO 3 3 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
8 parvathy 25 primi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
9 vivita 23 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
10 saindhavi 28 primi 1 37 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
11 Sudha  25 primi 2 38 1 TO 3 3 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.1 NORMAL 
NORM
AL NO NO 
12 Sudha  23 multi 1 37 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 3.2 ABNORM 
ABNOR
M YES NO 
13 amudham 26 multi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 3.1 NORMAL 
NORM
AL NO NO 
14 radha 26 primi 1 37 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 ABNORM 
NORM
AL NO NO 
15 padma 22 primi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 3 NORMAL 
NORM
AL NO NO 
16 jeeva 28 primi 2 38 4 TO 5 5 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
17 shamala 21 multi 3 39 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 ABNORM 
NORM
AL NO NO 
18 supriya 22 primi 4 40 4 TO 5 5 reactive YES NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
19 devi 20 multi 1 37 4 TO 5 5 reactive YES NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
20 Evangeline 26 multi 3 39 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 4 NORMAL 
NORM
AL NO NO 
21 barathy 26 primi 4 40 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
22 devaki 25 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 3.1 NORMAL 
NORM
AL NO NO 
23 vanathi 24 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
24 suganya 23 primi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
25 subha 24 primi 3 39 1 TO 3 2 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS YES YES 2 ABNORM 
ABNOR
M NO YES 
26 malini 21 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
27 tamil 22 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
28 niranjana 26 multi 1 37 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
29 ragavi 22 primi 3 39 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.4 NORMAL 
NORM
AL NO NO 
30 Ajidha 29 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.4 NORMAL 
NORM
AL NO NO 
31 lakshmi 23 primi 3 39 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
32 naga priya 25 primi 1 37 4 TO 5 4 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
33 shamala 21 primi 3 39 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
ABNOR
M YES NO 
34 Indumathi 26 primi 1 37 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.4 NORMAL 
NORM
AL NO NO 
35 sangavi 27 primi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.9 NORMAL 
NORM
AL NO NO 
36 delphin 24 primi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.9 NORMAL 
NORM
AL NO NO 
37 swetha 26 primi 3 39 4 TO 5 4 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
38 Kayani 20 primi 2 38 4 TO 5 5 reactive YES ABNORM NO   LN NO NO 3 ABNORM 
NORM
AL YES NO 
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39 shiva 27 multi 2 38 4 TO 5 4 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
40 shivam 21 primi 2 38 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
41 sunitha 25 primi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
42 sanjeevana 24 primi 2 38 4 TO 5 5 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
43 vedha 28 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 3 NORMAL 
NORM
AL NO NO 
44 janaki 26 multi 3 39 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.3 NORMAL 
NORM
AL NO NO 
45 pallavi 24 multi 2 38 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 3.4 NORMAL 
NORM
AL NO NO 
46 moulika 22 primi 1 37 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.1 NORMAL 
NORM
AL NO NO 
47 vinitha 23 multi 2 38 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
48 samanthi 23 multi 2 38 4 TO 5 4 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.2 NORMAL 
NORM
AL NO NO 
49 gaythri 29 multi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.9 NORMAL 
NORM
AL NO NO 
50 Rani  24 multi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
51 nandhini 21 multi 3 39 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.9 NORMAL 
NORM
AL NO NO 
52 chandra 22 primi 2 38 1 TO 3 3 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
53 saroja 21 multi 3 39 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
54 lavanya 27 primi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
55 sathya 19 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
56 latha 19 multi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
57 Ganga 25 multi 2 38 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.9 NORMAL 
NORM
AL NO NO 
58 Alagammai 28 primi 1 37 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
59 soundarya 26 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
60 kaleeshwari 21 primi 1 37 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 ABNORM 
NORM
AL NO NO 
61 Yamuna 24 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
62 Jeya 24 primi 1 37 4 TO 5 5 reactive YES NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
63 prasanna 24 multi 1 37 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
64 sharmila 27 multi 2 38 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.3 NORMAL 
NORM
AL NO NO 
65 amudha 22 primi 3 39 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
66 shanthi 23 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 ABNORM 
NORM
AL NO NO 
67 preethi 23 multi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
68 girija 26 primi 2 38 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
69 selvi 23 primi 1 37 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.4 NORMAL 
NORM
AL NO NO 
70 sunny 27 multi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
71 sundari 22 primi 4 40 4 TO 5 4 non react NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
72 shenba 27 primi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
73 evangeline 28 primi 1 37 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 ABNORM 
NORM
AL NO NO 
74 kavitha 21 multi 3 39 1 TO 3 3 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
75 Tamil Iniaya 24 multi 1 37 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
76 deepa 24 primi 3 39 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
77 jeya 26 primi 1 37 4 TO 5 4 reactive YES NORMAL NO   LN NO NO 2.4 NORMAL 
NORM
AL NO NO 
78 Punitha 28 multi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
79 Renuka  27 multi 1 37 4 TO 5 4 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.9 NORMAL 
NORM
AL NO NO 
106 
 
80 nimi 26 multi 3 39 4 TO 5 5 non react NO ABNORM NO 
MECONI
UM LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
81 sudar 25 primi 2 38 4 TO 5 5 reactive YES NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
82 Pushpa 28 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.1 NORMAL 
NORM
AL NO NO 
83 bhavya 20 primi 1 37 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
84 leela 22 multi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
85 shankari 21 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
86 Rani  24 primi 3 39 1 TO 3 3 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
87 janani 25 multi 2 38 1 TO 3 3 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
88 rita 23 primi 2 38 1 TO 3 3 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.9 ABNORM 
NORM
AL NO NO 
89 loganayaki 26 primi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
90 sheeba 27 primi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
91 parvathy 25 primi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
92 deepika 25 multi 3 39 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
93 sita 23 multi 1 37 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.4 NORMAL 
NORM
AL NO NO 
94 susila 26 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
95 indu 26 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
96 fathima 27 primi 3 39 1 TO 3 3 non react YES ABNORM YES 
MECONI
UM LSCS YES YES 1.9 ABNORM 
ABNOR
M NO YES 
97 venda 25 multi 1 37 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
98 parvathy 22 multi 2 38 4 TO 5 5 non react NO ABNORM NO 
MECONI
UM LSCS NO YES 3.2 NORMAL 
NORM
AL NO NO 
99 regina 26 primi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
100 chandra 25 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
101 varnam 19 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 3.1 NORMAL 
NORM
AL NO NO 
102 subadra 26 primi 1 37 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
103 mary 32 primi 1 37 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.2 ABNORM 
NORM
AL YES NO 
104 merlin 24 primi 1 37 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
105 hephzibah 22 multi 3 39 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
106 lekha 25 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
107 indira 27 primi 2 38 4 TO 5 4 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
108 lakshmi 27 primi 1 37 4 TO 5 5 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.4 NORMAL 
NORM
AL NO NO 
109 namitha 26 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
110 shenbagam 22 primi 1 37 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.5 NORMAL 
NORM
AL NO NO 
111 parameshwari 24 multi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.9 NORMAL 
NORM
AL NO NO 
112 Jagadhambal 24 primi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
113 saranya 26 primi 1 37 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
114 sukanya 24 primi 4 40 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 3.1 NORMAL 
NORM
AL NO NO 
115 bharathy 20 multi 1 37 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 3.5 ABNORM 
NORM
AL YES NO 
116 nethra 26 primi 2 38 4 TO 5 4 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
117 Hannah 25 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
118 anitha 25 multi 1 37 4 TO 5 5 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
119 menaga 22 primi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
120 hepzibah 25 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
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121 reshma 19 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
122 barani 26 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 3.5 NORMAL 
NORM
AL NO NO 
123 chandra 32 primi 3 39 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 ABNORM 
NORM
AL NO NO 
124 viji 22 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
125 Hema Malini 22 multi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.8 ABNORM 
NORM
AL YES NO 
126 sanjana 30 multi 1 37 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
127 sreeranjani 27 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
128 kannagi 29 primi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
129 celine 20 primi 1 37 4 TO 5 4 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
130 meena 26 multi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
131 lavanya 24 multi 1 37 4 TO 5 5 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
132 kavya 25 multi 3 39 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.4 NORMAL 
NORM
AL NO NO 
133 tina 26 multi 3 39 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
134 Gayathri 27 multi 1 37 4 TO 5 4 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
135 vasuki 24 primi 1 37 4 TO 5 5 non react NO ABNORM NO 
MECONI
UM LSCS NO YES 3.1 NORMAL 
NORM
AL NO NO 
136 shankari 27 primi 2 38 4 TO 5 4 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 ABNORM 
ABNOR
M YES NO 
137 neelavathy 24 multi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
138 sheela 24 primi 3 39 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.9 NORMAL 
NORM
AL NO NO 
139 preethi 23 multi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.7 ABNORM 
NORM
AL YES NO 
140 surekha 28 primi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
141 hanshitha 22 primi 1 37 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
142 preetha 28 multi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 ABNORM 
NORM
AL NO NO 
143 shakila 26 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 ABNORM 
NORM
AL NO NO 
144 Sangamithra 25 multi 1 37 4 TO 5 5 reactive YES NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
145 ambuja 24 primi 1 37 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
146 Reshma Beevi 22 multi 3 39 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
147 quincy 23 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
148 bakya 28 primi 2 38 4 TO 5 5 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
149 suganthi 28 multi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
150 shambu 24 primi 1 37 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.8 ABNORM 
NORM
AL NO NO 
151 maraim 28 primi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.4 NORMAL 
NORM
AL NO NO 
152 sneha 28 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 3 ABNORM 
NORM
AL NO NO 
153 dhanam 23 primi 1 37 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.9 ABNORM 
NORM
AL NO NO 
154 ajina 25 multi 3 39 1 TO 3 3 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
155 suman 25 primi 3 39 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.9 NORMAL 
NORM
AL NO NO 
156 usha 26 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
157 geetha 22 multi 2 38 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 ABNORM 
ABNOR
M YES NO 
158 riya 23 primi 1 37 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
159 sita 24 multi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 ABNORM 
NORM
AL NO NO 
160 bargavi 22 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
161 shantha 27 primi 4 40 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
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162 sangavi 27 primi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
163 mani 29 primi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
164 adhirai 25 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
165 pavithra 27 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
166 maria 22 primi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
167 malathy 20 multi 1 37 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
168 anu 22 multi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
169 prabha 23 primi 2 38 1 TO 3 3 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
170 anandhi 26 multi 3 39 4 TO 5 4 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 ABNORM 
NORM
AL NO NO 
171 deepika 23 multi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
172 sheela 27 primi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 3.2 NORMAL 
NORM
AL NO NO 
173 surya 24 multi 2 38 4 TO 5 5 reactive YES NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
174 fortuna 26 primi 4 40 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
175 rekha 26 multi 1 37 4 TO 5 4 reactive YES NORMAL NO   LN NO NO 2.5 NORMAL 
NORM
AL NO NO 
176 vijaya 24 multi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
177 divya 28 primi 1 37 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.9 NORMAL 
NORM
AL NO NO 
178 sumathy 24 primi 3 39 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
179 Devaki 23 primi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.8 NORMAL 
NORM
AL NO NO 
180 Garpaga Lakshmi 26 primi 4 40 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 3.1 NORMAL 
NORM
AL NO NO 
181 uma 29 primi 4 40 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
182 manali 27 multi 2 38 1 TO 3 3 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.2 ABNORM 
ABNOR
M YES NO 
183 saranya 24 multi 1 37 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 ABNORM 
ABNOR
M YES YES 
184 geetha 25 primi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
185 aruna 24 primi 1 37 4 TO 5 5 non react NO ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
186 deena 25 multi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
187 nithya 22 multi 2 38 4 TO 5 4 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.5 NORMAL 
NORM
AL NO NO 
188 ajitha 21 primi 3 39 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
189 ragini 24 primi 2 38 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 2.6 NORMAL 
NORM
AL NO NO 
190 Bhavani  23 primi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.9 NORMAL 
NORM
AL NO NO 
191 Sowmya 23 primi 3 39 4 TO 5 5 non react YES ABNORM NO 
MECONI
UM LSCS NO YES 3 NORMAL 
NORM
AL NO NO 
192 lina 22 multi 2 38 4 TO 5 4 non react NO ABNORM NO 
MECONI
UM LSCS NO YES 3.3 NORMAL 
NORM
AL NO NO 
193 priya 19 primi 3 39 4 TO 5 4 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.4 ABNORM 
ABNOR
M YES YES 
194 thenmozhi 24 multi 2 38 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.7 NORMAL 
NORM
AL NO NO 
195 regina 23 multi 1 37 4 TO 5 5 reactive NO NORMAL NO   LN NO NO 2.4 NORMAL 
NORM
AL NO NO 
196 keerthi 31 multi 2 38 4 TO 5 4 reactive NO NORMAL NO   LN NO NO 2.6 NORMAL 
NORM
AL NO NO 
197 neeta 29 primi 2 38 4 TO 5 5 reactive YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 2.4 NORMAL 
NORM
AL NO NO 
198 bojana 28 primi 3 39 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.8 NORMAL 
NORM
AL NO NO 
199 poornima 28 primi 3 39 4 TO 5 4 non react YES ABNORM NO 
FETAL 
DISTRESS LSCS NO YES 3.2 NORMAL 
NORM
AL NO NO 
200 Yazhini 26 primi 1 37 4 TO 5 5 reactive YES ABNORM NO 
MECONI
UM LSCS NO YES 2.7 NORMAL 
NORM
AL NO NO 
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